Issue 12/2022
Content (9 Articles)
Acknowledgement to Referees
Cell Biology of Parkin: Clues to the Development of New Therapeutics for Parkinson’s Disease
Jaimin Patel, Nikhil Panicker, Valina L. Dawson, Ted M. Dawson
Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson’s Disease: A Systematic Review and Bayesian Network Meta-analysis
Angelo Antonini, Rajesh Pahwa, Per Odin, Stuart H. Isaacson, Aristide Merola, Lin Wang, Prasanna L. Kandukuri, Ali Alobaidi, Connie H. Yan, Yanjun Bao, Cindy Zadikoff, Juan Carlos Parra, Lars Bergmann, K. Ray Chaudhuri
High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis
Léorah Freeman, Erin E. Longbrake, Patricia K. Coyle, Barry Hendin, Timothy Vollmer
A Multicenter, Randomized, Double-Blind, Positive-Controlled, Non-Inferiority, Phase III Clinical Trial Evaluating the Efficacy and Safety of Emulsified Isoflurane for Anesthesia Induction in Patients
Hui Yang, YuJun Zhang, ChuiLiang Liu, YangWen Ou, YuHang Zhu, Yun Xue, GaoFeng Zhao, YuShuang Lin, Chun Chen, GuoHai Xu, KaiMing Yuan, Qiang Wang, Min Zhang, LiE Li, Jin Liu, WenSheng Zhang
Thromboembolic Risks with Concurrent Direct Oral Anticoagulants and Antiseizure Medications: A Population-Based Analysis
Bonaventure Y. Ip, Ho Ko, Grace LH Wong, Terry CF Yip, Louis HS Lau, Alexander YL Lau, Xinyi Leng, Howan Leung, Howard HW Chan, Helen YF Chan, Vincent CT Mok, Yannie OY Soo, Thomas W. Leung
Evaluation of a Rapid Topiramate Titration Scheme for the Early Detection of Cognitive Side Effects
Juri-Alexander Witt, Guido Widman, Niels Hansen, Randi von Wrede, Christian E. Elger, Christoph Helmstaedter
Comment on: “A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention Deficit/Hyperactivity Disorder”
Alok Singh, Mahesh Kumar Balasundaram
Authors’ Reply to Singh and Balasundaram: Comment on “A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder”
Azmi Nasser, Joseph T. Hull, Tesfaye Liranso, Nicholas Fry, Andrew J. Cutler, Jonathan Rubin, Ann Childress